Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance
|
|
- Curtis Mathews
- 6 years ago
- Views:
Transcription
1 496126TAJ / Therapeutic Advances in Chronic DiseaseAH Sachdev and M Pimentel Therapeutic Advances in Chronic Disease Review Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance Amit H. Sachdev and Mark Pimentel Ther Adv Chronic Dis (2013) 4(5) DOI: / The Author(s), Reprints and permissions: journalspermissions.nav Abstract: Small intestinal bacterial overgrowth (SIBO) is defined as the presence of an abnormally high number of coliform bacteria in the small bowel. It is associated with a broad range of predisposing small intestinal motility disorders and with surgical procedures that result in bowel stasis. The most common symptoms associated with SIBO include diarrhea, flatulence, abdominal pain and bloating. Quantitative culture of small bowel contents and a variety of indirect tests have been used over the years in an attempt to facilitate the diagnosis of SIBO. The indirect tests include breath tests and biochemical tests based on bacterial metabolism of a variety of substrates. Unfortunately, there is no single valid test for SIBO, and the accuracy of all current tests remains limited due to the failure of culture to be a gold standard and the lack of standardization of the normal bowel flora in the small intestine. Currently, the ideal approach to treat SIBO is to treat the underlying disease, eradicate overgrowth, and address nutritional deficiencies that may be associated with the development of SIBO. Keywords: motility disorder, small intestinal bacterial overgrowth, testing, treatment Introduction Small intestinal bacterial overgrowth (SIBO) is a heterogeneous syndrome characterized by an increased number and/or abnormal type of bacteria in the small bowel. While some consider culture of the small bowel the gold standard for the diagnosis of SIBO based on the presence of bacteria [i.e. colony-forming units (cfu)] per ml of proximal jejunal aspiration, this designation was arbitrary and now the value has begun to be questioned by consensus and review of the literature [Gasbarrini et al. 2007; Khoshini et al. 2008]. Khoshini and colleagues suggest normal subjects rarely exceed cfu/ml and that this should be the defining threshold for SIBO [Khoshini et al. 2008]. Historically, the definition of SIBO is based on bacterial overgrowth in the context of abnormal or postsurgical anatomy. The characteristic situation where SIBO was most considered was in the stagnant loop syndrome. It is in this literature that investigators established the culture definition for bacterial overgrowth and the source of > cfu/ml criteria for SIBO. However, over the past three decades, there has been increasing suspicion of a bacterial overgrowth-like entity in many other nonsurgical gastrointestinal diseases. This has led scientists to question whether the definition of > cfu/ml (as defined by stagnant loop) can be used for other conditions. A systematic review conducted Khoshini and colleagues suggests that many gastrointestinal conditions have increased bacterial counts compared with healthy controls in the small bowel but below cfu/ml. This leads to the suspicion that the definition of SIBO based on culture is more indicative of stagnant loop and not SIBO, and that perhaps a definition of coliform bacteria cfu per ml of proximal jejunal aspiration as suggested by systematic review should be used as the definition of SIBO (Box 1). Box 1. Definition of small intestinal bacterial overgrowth (SIBO). Finding of coliform bacteria [i.e. colony-forming units (cfu)] per ml of proximal jejunal aspiration]. What is unique about SIBO is that there are excessive numbers of aerobic and anaerobic bacteria Correspondence to: Mark Pimentel, MD, FRCP(C) Director, GI Motility Program, Cedars-Sinai Medical Center, 8730 Alden Drive, Thalians Building, 2nd floor East, Los Angeles, CA 90048, USA pimentelm@cshs.org Amit H. Sachdev, MD Cedars-Sinai Medical Center, Los Angeles, CA, USA 223
2 Therapeutic Advances in Chronic Disease 4 (5) Table 1. Causes of small intestinal bacterial overgrowth. Causes Gastric achlorhydria Due to long term use of a proton pump inhibitor [Lombardo et al. 2010; Compare et al. 2011; Hamvas, 2012] or autoimmune etiology (chronic atrophic gastritis) Anatomic abnormality of the small intestine with stagnation Small intestine motility disorder Gastrocolic or coloenteric fistula Miscellaneous AIDS, acquired immunodeficiency syndrome; IgA, immunoglobulin A. Afferent limb of Billroth II gastrojejunostomy, small intestine diverticula [Krishnamurthy et al. 1983], obstruction, surgical blind loop, radiation enteritis Diabetic autonomic neuropathy, scleroderma, chronic intestinal pseudo-obstruction, small bowel diverticulosis, irritable bowel syndrome (IBS) [Pimentel et al. 2000] Crohn s disease [Funayama et al. 1999], malignancy, surgical resection AIDS, chronic pancreatitis (in 30 40% of cases [Trespi and Ferrieri, 1999]), liver cirrhosis (in up to 60% of patients), IgA deficiency, combined variable immunodeficiency, nonalchoholic steatohepatitis [Compare et al. 2012; Machado and Cortez-Pinto, 2012], fibromyalgia, celiac disease [Ghoshal et al. 2004; Krauss and Schuppan, 2006] colonizing the small intestine, a region usually containing few bacterial populations [Toskes, 1993; Bouhnik et al. 1999; Bures et al. 2010]. The bacteria typically recognized as SIBO are mainly of the colonic type and are thus predominantly gramnegative aerobes and anaerobic species that ferment carbohydrates into gas [Posserud et al. 2007; Sachdev and Pimental, 2012]. Common bacteria found in SIBO include Escherichia coli, Enterococcus spp., Klebsiella pneumonia and Proteus mirabilis, among others [Savage, 1977; Bouhnik et al. 1999; Frank et al. 2007; Frissora and Cash, 2007]. The SIBO hypothesis proposes that it is this expansion of bacteria into the small intestine from the large intestine that leads to symptoms including bloating, abdominal discomfort and changes in stool form [Pimentel and Lezcano, 2007]. Causes of gastrointestinal bacterial overgrowth Bacterial overgrowth occurs when intestinal stasis give the coliform bacteria the opportunity to proliferate locally. Mechanical stasis is an obvious cause of stasis in the gut and can be seen often in patients who have undergone previous gastrointestinal surgery. The classic of these is the surgical blind loop that allows for bacterial proliferation (see Table 1). Other prominent causes include diabetes, scleroderma, intestinal diverticulosis, afferent loop following a Billroth II gastrojenunostomy, and intestinal obstruction caused by strictures, adhesions, cancer and more recently irritable bowel syndrome (IBS). In addition, certain medications are associated with stasis and SIBO. For example, narcotics cause intestinal slowing and proton pump inhibitors (PPIs) reduce acid, which can lead to oral microbe penetration of the proximal gut [Lombardo et al. 2010; Compare et al. 2011; Hamvas, 2012]. In evaluating the mechanism of diarrhea in bacterial overgrowth, it is essential to realize that it is multifactorial. Hypothetical mechanisms are the following: 1. Bacteria digest carbohydrates, producing gas and osmotically active byproducts that promote osmotic diarrhea. 2. Bacteria and fatty acid byproducts injure the mucosa and contribute to diarrhea. 3. Mucosal injuries create lactase deficiencies. 4. Bacterial deconjugation of bile salts interferes with fat absorption and the absorption of fat-soluble vitamins. Most of these have not been determined by modern scientific method. However, the cause of SIBO also needs to be considered. For example, bowel obstruction or adhesions can cause bloating or distension in addition to SIBO. Prevalence The true prevalence of SIBO and its relationship to various disorders is largely unknown [Berlin, 224
3 AH Sachdev and M Pimentel Table 2. Clinical manifestations of small intestinal bacterial overgrowth. Nonspecific symptoms Bloating, flatulence, abdominal discomfort, diarrhea, abdominal pain Signs of malabsorption in Weight loss, steatorrhea, malnutrition, arthralgia extreme cases Clinical associations Irritable bowel syndrome [Simren et al. 2013] Rosacea[Parodi et al. 2008] Restless leg syndrome [Weinstock and Walters, 2011] Deficiency syndromes Macrocytic anemia (due to vitamin B12 deficiency) Microcytic anemia due to bleeding from ulcers in stagnant intestinal loops [Giannella and Toskes, 1976] Tetany in hypocalcaemia induced by vitamin D deficiency Metabolic bone disease [Di Stefano et al. 2001] Polyneuropathy due to vitamin B12 deficiency Other d-lactic acidosis- in patients with short bowel syndrome[bongaerts et al. 1997] 1987] because of the difficulty in its detection and definition [Cole and Ziegler, 2007]. It is particularly difficult to define its true prevalence because there is an association between SIBO and a number of other disorders and symptoms often overlap [Quigley and Abu-Shanab, 2010; Ghoshal et al. 2003]. Some patients may not seek healthcare and SIBO may not be properly diagnosed by medical investigations. Bacterial overgrowth may be asymptomatic or only present with nonspecific symptoms, and all symptoms might be incorrectly ascribed to the underlying disease (leading to SIBO) [Bouhnik et al. 1999]. In addition, the prevalence of SIBO is directly dependent on the characteristic of the study population and the diagnostic method used to detect or define bacterial overgrowth. If a breath test is used as the diagnostic method, prevalence varies further depending on the nature and dose of substrate used. In healthy people, SIBO has been described in % by the glucose breath test, 20 22% by the lactulose breath test and 0 35% by the 14 C d-xylose breath test [Khoshini et al. 2008]. Elderly patients may be especially susceptible to SIBO because of both a lack of gastric acid and the consumption of a disproportionately large number of drugs that can cause hypomotility [Quigley and Abu-Shanub, 2010]. In addition, depending on the disease or disorder, the literature on the prevalence of SIBO varies substantially. For instance, the prevalence of SIBO in IBS varies from 30 to 85% depending on the source used [Pimentel et al. 2000; Lin, 2004; Lupascu et al. 2005; Khoshini et al. 2008]. The prevalence of SIBO in liver cirrhosis is 50% [Pande et al. 2009] and in celiac disease, the prevalence of SIBO in some studies is also estimated to be 50% [Rubio-Tapia et al. 2009]. Interestingly, in asymptomatic morbidly obese patience the prevalence of SIBO was noted to be 17% [Sabate et al. 2008]. Clinical manifestations Although the symptoms of bacterial overgrowth are well known (Table 2), there are few studies that aim to scientifically characterize the symptoms. Since SIBO can be due to a number of local and systemic disorders, the symptoms of SIBO are distorted by symptoms of the underlying condition (scleroderma is a good example). The clinical manifestations of SIBO depend upon the severity of disease. While one would assume that the greater the quantity of bacteria, the greater the symptom, this has not been well studied. In Billroth II subjects, where coliform counts are cfu/ml these patients often develop significant malabsorption as well as the typical symptoms of bloating. It is not clear if the malabsorption is due to the nature of the surgery, the level of bacteria or other consequences. However, it is now believed that most patients with bacterial overgrowth do not have clinical malnutrition caused by malabsorption. In these cases the typical symptoms are nonspecific, and include distention, flatulence and diarrhea. Only rare instances (mostly associated with jejunoileal bypass surgery or short bowel syndrome) result in vitamin and mineral deficiencies, including the fat-soluble vitamins A or D, vitamin B12 and iron [Di Stefano et al. 2001]. Recently, data are accumulating to suggest that the most common association with SIBO is IBS and bacterial overgrowth may be part of the 225
4 Therapeutic Advances in Chronic Disease 4 (5) Table 3. Identification of small intestinal bacterial overgrowth (SIBO) in a patient. Physical examination Laboratory tests Direct tests Indirect tests Other diagnostic tests Imaging/colonoscopy Nonspecific findings: abdominal distension, small intestinal succession splash [Taylor et al. 1991], scarring associated with prior surgeries, severe cases may have latent tetany, polyneuropathy and skin manifestations (rosacea) Anemia, low vitamin B12, signs of malnutrition (lymphopenia, low serum pre-albumin and transferrin), elevated serum folate and vitamin K levels (bacteria produce these) Quantitative culture of luminal contents Breath tests: 14 C d-xylose, hydrogen Urinary tests, serum test Barium studies, CT enterography to identify mechanical causes of SIBO CT, computerized tomography. pathogenesis of this condition [Pimentel et al. 2006; Fumi and Trexler, 2008]. In addition, SIBO has been reported with rosacea, a dermatological skin condition affecting the face [Parodi et al. 2008]. d-lactic acidosis is a severe complication of patients with short bowel syndrome (with intact large bowel). It is caused by an excessive overgrowth of lactobacilli. In clinically expressed cases, symptoms comprise characteristic neurologic abnormalities including confusion, cerebellar ataxia, slurred speech and loss of memory, and patients may exhibit some degree of altered mental status [Bures et al. 2010]. Diagnosis There are many ways to diagnose SIBO but the diagnosis often starts with clinical suspicion and history of risk factors for SIBO (Table 3). Currently, there is no adequately validated diagnostic test for SIBO despite decades of its recognition as a clinical entity [Khoshini et al. 2008]. Physical examination and laboratory tests can be used, although findings are nonspecific. The gold standard used in diagnosis was quantitative culture of jejunal aspirates demonstrating > cfu/ml of fluid; however, this value is not validated and recently suggested to be more accurately assessed as > cfu/ml by systematic review [Khoshini et al. 2008]. Breath testing, and specifically the hydrogen breath test, aid in the diagnosis. Noninvasive breath tests have been shown to have a sensitivity of 60 90% and specificity of 85%, although validation with culture is limited [Khoshini et al. 2008]. Stools studies can also be used to corroborate the presence of steatorrhea. In addition, small bowel barium radiography or computerized tomography (CT) enetrography can be used to identify mechanical factors predisposing to intestinal stasis. Direct tests for SIBO Measurement of the bacterial colony count. As described above, the most widely accepted test for SIBO is quantitative culture of luminal contents, and values > cfu/ml are traditionally felt to be abnormal. However, recent data support the argument that this value is too high and represents only the degree of SIBO found in surgically altered patients [Khoshini et al. 2008]. Based on normal human small bowel culture, the definition of SIBO appears more likely counts >10 3 cfu/ml. During culture, the proper technique for collection of the specimen for the culture is not well defined. A sterile catheter passed through the instrument channel of an upper endoscope has the means of collecting a specimen free of contamination by saliva and other secretions. Culture techniques on the aspirated sample also vary. The sample is often plated on nonselective media. There are concerns with culture as a standard as well. One major concern is the inability to gain access to more distal segments of the small bowel, as only the upper small bowel is accessible using standard techniques. The test is also expensive and some risk since it requires endoscopy or fluoroscopy to place the aspiration catheters. Other limitations of jejunal aspirates include the fact that very few of the gut bacteria can be identified or cultured since there are species of bacteria in the bowel, and most of them cannot be 226
5 AH Sachdev and M Pimentel routinely cultured [Quigley and Abu-Shanub, 2010], and contamination with oropharyngeal flora frequently occurs during collection of the specimen. In addition, the bacterial overgrowth may be patchy and missed by a single aspiration, or located in relatively inaccessible sites [Fan and Sellin, 2009]. Therefore, due to all of these limitations, cultures are not commonly performed. Indirect tests for SIBO Breath tests. Breath tests are now widely used as an alternative to direct aspiration because they are noninvasive and less expensive. Breath tests that are commonly used include the 14 C d-xylose breath test and hydrogen breath tests. The 14 C d-xylose breath test depends on the capacity of the intestinal bacteria to release 14 C CO 2 which is absorbed and ultimately eliminated in the breath where it can be quantified. Radioactive 14 C or the stable isotope 13 C can be used to label 1 g of xylose. The sensitivity of 14 C d-xylose test ranges from 14.3% to 95%, and specificity from 40% to 94% [King and Toskes, 1986; Riordan et al. 1995]. However, it is not commonly performed in clinical practice because it is not widely available and has been largely replaced by hydrogen breath tests which are considered to be more accurate [Kerlin and Wong, 1988; Riordan et al. 1996; Stotzer and Kilander, 2000]. In addition, disorders associated with impaired gastric emptying may lead to false negative results, while rapid intestinal emptying may lead to false-positive results due to early presentation of the test substrate in the colon. Hydrogen breath tests are based on the principle that carbohydrate fermentation by the gut flora, primarily anaerobic bacteria in the colon, is the only source of hydrogen in the body. When colonic bacteria colonize the small intestine, as in SIBO, fermentation of carbohydrates in the small intestine produces a large and premature amount of hydrogen gas. H 2 produced in this manner diffuses into the systemic circulation and is excreted via the lungs in expelled air. Hydrogen breath tests are performed following a 12-hour overnight fast and consumption of a low fiber diet for 1 day. Patients are asked to exhale into a tube connected to a bag and H 2 baseline values are obtained before intake of a fermentable substrate. The carbohydrate substrate (glucose, lactulose or xylose) is then administered orally and a sequential end-expiratory breath is taken every 15 minutes for 3 hours. Owing to their low costs and relative simplicity, hydrogen breath tests are the most common of all the breath tests used to diagnose SIBO and of these, the lactulose hydrogen breath test (LHBT) is the most widely used hydrogen breath test. The increase in hydrogen level after lactulose ingestion was first reported by Bond and Levitt [Bond and Levitt, 1972]. In this case, intestinal flora ferment the lactulose, resulting in the production of hydrogen and/or methane. After the administration of 10 g of the lactulose, breath samples are taken at 15-minute intervals for 3 hours. The criteria for a positive breath test are also problematic and not well validated. However, the most commonly used technique is to recognize a rise in hydrogen of greater than 20 parts per million (ppm) and a double peak on the breath hydrogen expiration graph. The first peak is caused by production of the gas due to the presence of bacterial overgrowth in the small bowel; the second results from the action of cecal flora on the lactulose. Most investigators accept that the first rise in H 2 be within 90 minutes of lactulose ingestion. It is also important to note that since the breath tests are simpler to perform, they are a reasonable choice for screening and monitoring of therapy. Other tests. A variety of other tests have also been used to diagnose SIBO. Imaging studies are useful for the identification of causative factors such as jejunal diverticulosis. Biopsies are usually not very effective because mucosal injury and villous atrophy are only present in the most severely affected individuals [Quigley and Abu-Shanub, 2010]. Urinary choly p-aminobenzoic acid (choly-paba) and indican can also be used to detect SIBO [Khoshini et al. 2008]. Various serum makers such as bile acids, folic acid and cobalamin have also been proposed, but none have the diagnostic accuracy necessary for use in the diagnosis of SIBO [Quigley and Abu-Shanub, 2010]. Treatment Treatment for SIBO is complex and must be individualized. The three main components in treating patients with SIBO are shown in Box 2. It is important to address all causes, symptoms and complications associated with SIBO. Where physical causes are responsible, the best way to 227
6 Therapeutic Advances in Chronic Disease 4 (5) Box 2. Principles of treating small intestinal bacterial overgrowth (SIBO) [Quigley and Abu-Shanub, 2010]. 1. Treat the underlying disease or condition. 2. Eradicate overgrowth 3. Address associated nutritional deficiencies. treat bacterial overgrowth is to correct the anatomic defect that has potentiated the overgrowth (e.g. adhesions, bowel obstruction, strictures). In other cases, treatment for bacterial overgrowth includes eliminating drugs that reduce intestinal motility or reduce gastric acidity. Dietary manipulation may also assist in the treatment of SIBO [Vanderhoof et al. 1998]. In many patients, it is necessary to exclude lactose from the diet, to reduce other simple sugars, to increase coverage of energy needs by fat and to administer mediumchain triacylglycerol (MCT) oils [Bures et al. 2010]. In cases where there is decreased motility, such as chronic pseudo-obstruction, methods to enhance motility can be attempted. Prokinetic agents that are commonly used and are available in the US include metoclopramide and erythromycin. In Europe, this could include prucalopride although this has not specifically studied in SIBO [Parodi et al. 2008]. In situations where a PPI is a suspected contributor to bacterial overgrowth, lifestyle measures for treatment of gastroesophageal reflux disease (GERD) or a reduction in acid suppression to the lowest possible dose for and shortest duration may be beneficial in alleviating symptoms of overgrowth. Despite efforts to treat the primary cause of SIBO above, most patients require treatment with antibiotics. Antibiotic treatment should selectively target those bacterial strains that cause SIBO. The goal of treatment with antibiotics is to reduce rather than eradicate the flora, leading to symptomatic improvement. Ideally, the choice of antibiotics could be based on bacterial sensitivity testing to particular antibiotics [Singh and Toskes, 2004]. However, this would require culture in a large number of subjects and the limitation of culture as already discussed [Quigley and Abu-Shanub, 2010]. There is no common agreement concerning the choice, dosing and duration of antibiotic therapy. Broad spectrum antibiotics which affect enteric aerobes and anaerobes and numerous choices are available (Box 3). These include ciprofloxacin, norfloxacin, amoxicillin/clavulanate, metronidazole, cephalexin and more recently rifaximin. Rifaximin has gained popularity since it is nonabsorbed, has few side effects and little evidence for resistance [Frissora and Cash, 2007; Koo and Dupont, 2010]. Rifaximin may therefore be the antibiotic of choice as clinical resistance is seen far less frequent than with other antibiotics [Vanderhoof et al. 1998; Yang et al. 2008; Rabenstein et al. 2011; Di Stefano et al. 2000]. Box 3. Antibiotic treatment options for small intestinal bacterial overgrowth (SIBO). Rifaximin Ciprofloxacin Norfloxacin [Attar et al. 1999] Amoxicillin/clavulanate [Attar et al. 1999] Metronidazole + trimethoprin/ sulfamethoxazole [Malik et al. 2011] Metronidazole + cephalexin [Malik et al. 2011] Regardless of the antibiotic used, the patient will need to be retreated and in some cases require long-term antibiotic use (e.g. widespread small intestinal diverticulosis). In more conventional cases, it is commonplace to repeat breath testing if symptoms of abdominal pain, diarrhea, bloating, and flatulence relapse [Lauritano et al. 2008]. There are no controlled trials to guide the duration of treatment or management of recurrent SIBO and recommendations are commonly based on clinical experience although successful treatment of recurrence with rifaximin has been reported [Pimentel et al. 2011]. Conclusion SIBO is defined as an increase in the number of bacteria in the small bowel. While there are a number of different causes of SIBO, SIBO is often misdiagnosed or underdiagnosed due to the variety of clinical manifestations, and treatment must be individualized with a focus on eradicating the underlying disease. While antibiotics remain the mainstay of therapy, attention to understanding the mechanism of SIBO in any given patient is important to help implement a strategy to prevent relapse
7 AH Sachdev and M Pimentel Funding This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors. Conflict of interest statement The authors declare no conflicts of interest in preparing this article. References Attar, A., Flourie, B., Rambaud, J., Franchisseur, C., Ruszniewski, P. and Bouhnik, Y. (1999) Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117: Berlin, R. (1987) Pica, paper and porphyria. Lancet 2: Bond, J., Jr and Levitt, M. (1972) Use of pulmonary hydrogen (H 2 ) measurements to quantitate carbohydrate absorption. Study of partially gastrectomized patients. J Clin Invest 51: Bongaerts, G., Tolboom, J., Naber, A., Sperl, W., Severijnen, R., Bakkeren, J. et al. (1997) Role of bacteria in the pathogenesis of short bowel syndromeassociated d-lactic acidemia. Microb Pathog 22: Bouhnik, Y., Alain, S., Attar, A., Flourie, B., Raskine, L., Sanson-Le Pors, M. et al. (1999) Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 94: Bures, J., Cyrany, J., Kohoutova, D., Forstl, M., Rejchrt, S., Kvetina, J. et al. (2010) Small Intestinal bacterial overgrowth syndrome. World J Gastroenterol 16: Cole, C. and Ziegler, T. (2007) Small Bowel bacterial overgrowth: a negative factor in gut adaptation in pediatric SBS. Curr Gastroenterol Rep 9: Compare, D., Coccoli, P., Rocco, A., Nardone, O., De Maria, S., Carteni, M. et al. (2012) Gut liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 22: Compare, D., Pica, L., Rocco, A., De Giorgi, F., Cuomo, R., Sarnelli, G. et al. (2011) Effects of longterm PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 41: Di Stefano, M., Strocchi, A., Malservisi, S., Veneto, G., Ferrieri, A. and Corazza, G. (2000) Nonabsorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 14: Di Stefano, M., Veneto, G., Malservisi, S. and Corazza, G. (2001) Small intestine bacterial overgrowth and metabolic bone disease. Dig Dis Sci 46: Fan, X. and Sellin, J. (2009) Review article: small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. Aliment Pharmacol Ther 29: Frank, D., St Amand, A., Feldman, R., Boedeker, E., Harpaz, N. and Pace, N. (2007) Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104: Frissora, C. and Cash, B. (2007) Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 25: Fumi, A. and Trexler, K. (2008) Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 42: Funayama, Y., Sasaki, I., Naito, H., Fukushima, K., Shibata, C., Masuko, T. et al. (1999) Monitoring and antibacterial treatment for postoperative bacterial overgrowth in Crohn s disease. Dis Colon Rectum 42: Gasbarrini, A., Lauritano, E., Gabrielli, M., Scarpellini, E., Lupascu, A., Ojetti, V. et al. (2007) Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 25: Ghoshal, U., Ghoshal, U., Misra, A. and Choudhuri, G. (2004) Partially responsive celiac disease resulting from small intestinal bacterial overgrowth and lactose intolerance. BMC Gastroenterol 4: 10. Ghoshal, U., Ghoshal, U., Ranjan, P., Naik, S. and Ayyagari, A. (2003) Spectrum and antibiotic sensitivity of bacteria contaminating the upper gut in patients with malabsorption syndrome from the tropics. BMC Gastroenterol 3: 9. Giannella, R. and Toskes, P. (1976) Gastrointestinal bleeding and iron absorption in the experimental blind loop syndrome. Am J Clin Nutr 29: Hamvas, J. (2012) [Proton-pump inhibitor therapy and small bowel bacterial contamination]. Orv Hetil 153: Kerlin, P. and Wong, L. (1988) Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 95: Khoshini, R., Dai, S., Lezcano, S. and Pimentel, M. (2008) A Systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 53:
8 Therapeutic Advances in Chronic Disease 4 (5) King, C. and Toskes, P. (1986) Comparison of the 1-gram [14C]xylose, 10-gram lactulose-h2, and 80-gram glucose-h2 breath tests in patients with small intestine bacterial overgrowth. Gastroenterology 91: Koo, H. and Dupont, H. (2010) Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 26: Krauss, N. and Schuppan, D. (2006) Monitoring nonresponsive patients who have celiac disease. Gastrointest Endosc Clin N Am 16: Krishnamurthy, S., Kelly, M., Rohrmann, C. and Schuffler, M. (1983) Jejunal diverticulosis. A heterogenous disorder caused by a variety of abnormalities of smooth muscle or myenteric plexus. Gastroenterology 85: Lauritano, E., Gabrielli, M., Scarpellini, E., Lupascu, A., Novi, M., Sottili, S. et al. (2008) Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 103: Lin, H. (2004) Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 292: Lombardo, L., Foti, M., Ruggia, O. and Chiecchio, A. (2010) Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 8: Lupascu, A., Gabrielli, M., Lauritano, E., Scarpellini, E., Santoliquido, A., Cammarota, G. et al. (2005) Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 22: Machado, M. and Cortez-Pinto, H. (2012) Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 11: Malik, B., Xie, Y., Wine, E. and Huynh, H. (2011) Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. Can J Gastroenterol 25: Pande, C., Kumar, A. and Sarin, S. (2009) Smallintestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther 29: Parodi, A., Paolino, S., Greco, A., Drago, F., Mansi, C., Rebora, A. et al. (2008) Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 6: Parodi, A., Sessarego, M., Greco, A., Bazzica, M., Filaci, G., Setti, M. et al. (2008) Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 103: Pimentel, M., Chow, E. and Lin, H. (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95: Pimentel, M. and Lezcano, S. (2007) Irritable bowel syndrome: bacterial overgrowth what s known and what to do. Curr Treat Options Gastroenterol 10: Pimentel, M., Morales, W., Chua, K., Barlow, G., Weitsman, S., Kim, G. et al. (2011) Effects of rifaximin treatment and retreatment in nonconstipated ibs subjects. Dig Dis Sci 56: Pimentel, M., Park, S., Mirocha, J., Kane, S. and Kong, Y. (2006) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145: Posserud, I., Stotzer, P., Bjornsson, E., Abrahamsson, H. and Simren, M. (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56: Quigley, E. and Abu-Shanab, A. (2010) Small intestinal bacterial overgrowth. Infect Dis Clin North Am 24: , viii ix. Rabenstein, T., Fromm, M. and Zolk, O. (2011) [Rifaximin a non-resorbable antibiotic with many indications in gastroenterology]. Z Gastroenterol 49: Riordan, S., McIver, C., Duncombe, V., Bolin, T. and Thomas, M. (1995) Factors Influencing the 1-g 14C-d-xylose breath test for bacterial overgrowth. Am J Gastroenterol 90: Riordan, S., McIver, C., Walker, B., Duncombe, V., Bolin, T. and Thomas, M. (1996) The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 91: Rubio-Tapia, A., Barton, S., Rosenblatt, J. and Murray, J. (2009) Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. J Clin Gastroenterol 43: Sabate, J., Jouet, P., Harnois, F., Mechler, C., Msika, S., Grossin, M. et al. (2008) High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg 18: Sachdev, A. and Pimentel, M. (2012) Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 14: Savage, D. (1977) Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 31:
9 AH Sachdev and M Pimentel Simren, M., Barbara, G., Flint, H., Spiegel, B., Spiller, R., Vanner, S. et al. (2013) Intestinal microbiota in functional bowel disorders: a Rome Foundation report. Gut 62: Singh, V. and Toskes, P. (2004) Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 7: Stotzer, P. and Kilander, A. (2000) Comparison of the 1-gram (14)C-d-xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. Digestion 61: Taylor, S., Sondheimer, J., Sokol, R., Silverman, A. and Wilson, H. (1991) Noninfectious colitis associated with short gut syndrome in infants. J Pediatr 119: Toskes, P. (1993) Bacterial overgrowth of the gastrointestinal tract. Adv Intern Med 38: Trespi, E. and Ferrieri, A. (1999) Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin 15: Vanderhoof, J., Young, R., Murray, N. and Kaufman, S. (1998) Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 27: Weinstock, L. and Walters, A. (2011) Restless legs syndrome is associated with irritable bowel syndrome and small intestinal bacterial overgrowth. Sleep Med 12: Yang, J., Lee, H., Low, K., Chatterjee, S. and Pimentel, M. (2008) Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 53: Visit SAGE journals online SAGE journals 231
SIBO
SIBO What is it? Small Intestinal Bowel Overgrowth A chronic bacterial infection of the small intestine Caused by bad bacteria such as E Coli and Clostridium migrating to the small intestine There is not
More informationRifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth
Aliment Pharmacol Ther 2005; 22: 31 35. doi: 10.1111/j.1365-2036.2005.02516.x Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth E. C. LAURITANO, M. GABRIELLI, A. LUPASCU,
More informationIrritable bowel syndrome (IBS) is a functional gastrointestinal. Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome INTRODUCTION
Bacteria and the Role of Antibiotics in Irritable Bowel Syndrome by Mark Pimentel Although several pathophysiologic models have been suggested, the etiology of irritable bowel syndrome (IBS) is unknown.
More informationLevel 2. Non Responsive Celiac Disease KEY POINTS:
Level 2 Non Responsive Celiac Disease KEY POINTS: Celiac Disease (CD) is an autoimmune condition triggered by ingestion of gluten leading to intestinal damage and a variety of clinical manifestations.
More informationOutcome of breath tests in adult patients with suspected small intestinal bacterial overgrowth
Gastroenterology and Hepatology From Bed to Bench. 207 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Outcome of breath tests in adult patients with suspected small
More informationFecal incontinence causes 196 epidemiology 8 treatment 196
Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea
More informationProton pump inhibitors (PPIs) are potent drugs producing
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:504 508 Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy LUCIO LOMBARDO,* MONICA FOTI,* OLGA RUGGIA,* and
More informationAntibiotic treatment of small bowel bacterial overgrowth in patients with Crohn s disease
Aliment Pharmacol Ther 2003; 18: 1107 1112. doi: 10.1046/j.1365-2036.2003.01800.x Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn s disease F. CASTIGLIONE, A. RISPO, E.
More informationMicrobiome and Small Intestinal Bacterial Overgrowth
Microbiome and Small Intestinal Bacterial Overgrowth Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital equigley@houstonmethodist.org
More informationMalabsorption: etiology, pathogenesis and evaluation
Malabsorption: etiology, pathogenesis and evaluation Peter HR Green NORMAL ABSORPTION Coordination of gastric, small intestinal, pancreatic and biliary function Multiple mechanisms Fat protein carbohydrate
More informationGastroenterology and Feeding Issues in Fanconi Anemia
Gastroenterology and Feeding Issues in Fanconi Anemia Sarah Jane Schwarzenberg, MD Pediatric Gastroenterology, Hepatology and Nutrition August 12, 2012 GI problems in FA 5% have gastrointestinal tract
More informationSmall Intestinal Bacterial Overgrowth. Lela Altman, ND, EAMP Adjunct Faculty and Clinical Supervisor at the Bastyr Center for Natural Health
Small Intestinal Bacterial Overgrowth Lela Altman, ND, EAMP Adjunct Faculty and Clinical Supervisor at the Bastyr Center for Natural Health Acknowledgements Special thanks to Eric Schoen (ND Candidate),
More informationXifaxan. Xifaxan (rifaximin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.34 Subject: Xifaxan Page: 1 of 6 Last Review Date: December 8, 2017 Xifaxan Description Xifaxan (rifaximin)
More informationThe place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis
Research paper The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis Ali Rezaie 1, Shekoufeh Nikfar 2, Mohammad Abdollahi 3 1 Faculty of Medicine, University
More informationIJBPAS, December, 2014, 3(12): SMALL INTESTINE BACTERIAL OVERGROWTH IN IRANIAN IRRITABLE BOWEL SYNDROME PATIENTS
: 3041-3050 ISSN: 2277 4998 SMALL INTESTINE BACTERIAL OVERGROWTH IN IRANIAN IRRITABLE BOWEL SYNDROME PATIENTS RAHMATOLLAH RAFIEI 1, MITRA SHAVAKHI 2, LOOTFOLLAH FOULADI 3, MOHAMMAD ARASH RAMEZANI 4 AND
More informationMicrobiome GI Disorders
Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things
More informationTips for Managing Celiac Disease. Robert Berger MD FRCPC Gastroenterology New Brunswick Internal Medicine Update April 22, 2016
Tips for Managing Celiac Disease Robert Berger MD FRCPC Gastroenterology New Brunswick Internal Medicine Update April 22, 2016 Disclosures None relevant to this presentation Objectives Briefly review the
More informationNew Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome
New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome Soojong Hong Chae, MD Clinical Assistant Professor Digestive Diseases and Nutrition University of South Florida ROME III Functional dyspepsia
More informationNew Directions in Lactose Intolerance: Moving from Science to Solutions
New Directions in Lactose Intolerance: Moving from Science to Solutions PAPANDREOU DIMITRIOS, PhD, MS., RD. Ass. Professor of Nutrition, University of Nicosia A Barrier to Dairy Consumption Lactose intolerance
More informationM. Furnari, A. Parodi, L. Gemignani, E. G. Giannini, S. Marenco, E. Savarino, L. Assandri, V. Fazio, D. Bonfanti, S. Inferrera & V.
Alimentary Pharmacology and Therapeutics Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial
More informationShort Bowel Syndrome: Medical management
Short Bowel Syndrome: Medical management La Sindrome dell'intestino Corto in età pediatrica Brescia 18 marzo 2011 Jon A.Vanderhoof, M.D. Division of Pediatric GI Harvard Medical School Children s Hospital,
More informationSmall Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results
Small Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results Martin Carr, M.D. March 3, 2018 Good evening everyone, this is Martin Carr, and I
More informationCHRONIC DIARRHEA DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE THAN 4 WEEKS
DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (403) 270-7479 CHRONIC DIARRHEA DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE
More informationSpectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
More informationWilliam Chey, MD University of Michigan Ann Arbor, MI
Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly
More informationLower Gastrointestinal Tract KNH 406
Lower Gastrointestinal Tract KNH 406 Lower GI Tract A&P Small Intestine Anatomy Duodenum, jejunum, ileum Maximum surface area for digestion and absorption Specialized enterocytes from stem cells of crypts
More informationBiomarkers of GI tract diseases. By Dr. Gouse Mohiddin Shaik
By Dr. Gouse Mohiddin Shaik Introduction The gastrointestinal (GI) tract is a complex system performing multiple biological functions which are anatomically distributed Site for food processing and absorption
More informationEffect of dietary fiber on intestinal gas production and small bowel transit time in man13
ffect of dietary fiber on intestinal gas production and small bowel transit time in man13 John H. Bond,4 M.D. and Michael D. Levitt,5 M.D. ABSTRACT The influence of dietary fiber on intestinal gas production
More informationGastroenterology. Certification Examination Blueprint. Purpose of the exam
Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist
More informationNutritional assessments and diagnosis of digestive disorders
Nutritional assessments and diagnosis of digestive disorders AASER ABDELAZIM Assistant professor of Medical Biochemistry Zagazig University, Egypt University of Bisha, KSA aaserabdelazim@yahoo.com 7 Mal
More informationPostgastrectomy Syndromes
Postgastrectomy Syndromes Postgastrectomy syndromes are iatrogenic conditions that may arise from partial gastrectomies, independent of whether the gastric surgery was initially performed for peptic ulcer
More informationHome Total Parenteral Nutrition for Adults
Home Total Parenteral Nutrition for Adults Policy Number: Original Effective Date: MM.08.007 05/21/1999 Line(s) of Business: Current Effective Date: PPO, HMO, QUEST Integration 05/27/2016 Section: Home
More informationIBS - Definition. Chronic functional disorder of GI generally characterized by:
IBS - Definition Chronic functional disorder of GI generally characterized by: 3500 3000 No. of Publications 2500 2000 1500 1000 Irritable Bowel syndrome Irritable Bowel Syndrome 500 0 1968-1977 1978-1987
More informationDigestion and Absorption
Digestion and Absorption Digestion and Absorption Digestion is a process essential for the conversion of food into a small and simple form. Mechanical digestion by mastication and swallowing Chemical digestion
More informationDetermination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2015.30.6.757 J Korean Med Sci 2015; 30: 757762 Determination of Rifaximin Treatment Period According to Lactulose Breath Test
More informationSmall-Bowel and colon Transit. Mahsa Sh.Nezami October 2016
Small-Bowel and colon Transit Mahsa Sh.Nezami October 2016 Dyspeptic symptoms related to dysmotility originating from the small bowel or colon usually include : Abdominal pain Diarrhea Constipation However,
More informationIntegrating Novel Diagnostic Strategies into Practice: Key Points. Stanley Cohen, MD Emory University Atlanta, Georgia
Integrating Novel Diagnostic Strategies into Practice: Key Points Stanley Cohen, MD Emory University Atlanta, Georgia Disclosure Research: Janssen, Covidien/Medtronics, AbbVie, AstraZeneca and QOL Speaker:
More informationChronic diarrhea. Dr.Nasser E.Daryani Professor of Tehran Medical University
1 Chronic diarrhea Dr.Nasser E.Daryani Professor of Tehran Medical University Timing Acute diarrhea: 4 weeks Definitions Derived from Greek
More informationAmyloidosis & the GI Tract
Amyloidosis & the GI Tract John O. Clarke, M.D. Director, Esophageal Program Clinical Associate Professor of Medicine Stanford University john.clarke@stanford.edu 2017 Topics to cover 1) Patterns of GI
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationSheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Department of Medicine University of California, San Diego
Severe and Emergency Presentations of Celiac Disease Sheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Department of Medicine University of California, San Diego Case Presentation (1) 63 year old male transferred
More informationTesting for Small Intestinal Bacterial Overgrowth (SIBO)
Testing for Small Intestinal Bacterial Overgrowth (SIBO) Sharon Erdrich MHSc (Hons), DipNat, DipHerbMed, DipAroma, NZRN. 2018 Sharon Erdrich 1 TOPICS 1. Intro to SiBO Clinical Presentation of SiBO 2. Options
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationSmall intestine bacterial overgrowth in patients with irritable bowel syndrome
European Review for Medical and Pharmacological Sciences 2008; 12: 197-202 Small intestine bacterial overgrowth in patients with irritable bowel syndrome M. CARRARA, S. DESIDERI, M. AZZURRO, G.M. BULIGHIN,
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationGastrointestinal, Hepatic, and Nutritional Challenges in FA
Gastrointestinal, Hepatic, and Nutritional Challenges in FA Sarah Jane Schwarzenberg, MD Pediatric Gastroenterology, Hepatology and Nutrition June 29, 2014 GI problems in FA 5% have gastrointestinal tract
More informationNon-Invasive Assessment of Intestinal Function
Overview Non-Invasive Assessment of Intestinal Function Introduction This paper will demonstrate that the 13 C-sucrose breath test ( 13 C-SBT) determines the health and function of the small intestine.
More informationPARENTERAL NUTRITION THERAPY
UnitedHealthcare Benefits of Texas, Inc. 1. UnitedHealthcare of Oklahoma, Inc. 2. UnitedHealthcare of Oregon, Inc. UnitedHealthcare of Washington, Inc. UnitedHealthcare West BENEFIT INTERPRETATION POLICY
More informationGuidelines NICE, not NICE and the Daily Mail. Dr Andy Poullis Consultant Gastroenterologist
Guidelines NICE, not NICE and the Daily Mail 2018 Dr Andy Poullis Consultant Gastroenterologist Coeliac IBS Gall bladder polyps PEI PPI Who to test for Coeliac persistent unexplained abdominal or gastrointestinal
More informationGASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint
GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments
More informationBloating, Flatulence, and
A 45-Year-Old Man With Recurrent Abdominal Pain, Bloating, Flatulence, and Intermittent Loose Stools Anthony J. Lembo, MD Associate Professor of Medicine Harvard Medical School Director, GI Motility Laboratory
More informationEver wonder what s really happening on the inside?
For Practitioners Ever wonder what s really happening on the inside? Are your patients suffering from diarrhea, constipation, bloating, gas or indigestion? Rocky Mountain Analytical is now offering Gut-Well
More informationFormulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.
Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01
More informationUTI IN ELDERLY. Zeinab Naderpour
UTI IN ELDERLY Zeinab Naderpour Urinary tract infection (UTI) is the most frequent bacterial infection in elderly populations. While urinary infection in the elderly person is usually asymptomatic, symptomatic
More informationCHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University
CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University 1 Definition of FGID Chronic and recurrent symptoms of the gastrointestinal
More informationMassachusetts ACP Meeting Update in Gastroenterology and Hepatology
Massachusetts ACP Meeting Update in Gastroenterology and Hepatology November 19 th, 2016 Norton J. Greenberger, MD Senior Attending Physician Brigham and Women s Hospital 1 Agenda Stomach and Small Bowel
More informationTreatment of Bacterial Overgrowth in Patients With Irritable Bowel Syndrome
Treatment of Bacterial Overgrowth in Patients With Irritable Bowel Syndrome Background: Rifaximin is an effective treatment of irritable bowel syndrome (IBS) with small intestinal bacterial overgrowth
More informationT H E B E T T E R H E A L T H N E W S
Dr. Paul G. Varnas & WholeHealthAmerica.com present V O L U M E 1 3, I S S U E 4 T H E B E T T E R H E A L T H N E W S A P R I L, 2 0 1 6 M O R E P R O B L E M S W I T H P R O T O N P U M P I N H I B I
More informationSmall Intestinal Bacterial Overgrowth: Updates and Clinical Implications. Christine Stubbe, ND, FABNO
Small Intestinal Bacterial Overgrowth: Updates and Clinical Implications Christine Stubbe, ND, FABNO Lahnor Powell, ND, MPH Medical Education Specialist - Atlanta Christine Stubbe, ND, FABNO Technical
More informationSmall bowel bacterial overgrowth and type 1 diabetes
European Review for Medical and Pharmacological Sciences 2009; 13: 419-423 Small bowel bacterial overgrowth and type 1 diabetes V. OJETTI, D. PITOCCO*, E. SCARPELLINI, F. ZACCARDI, F. SCALDAFERRI, G. GIGANTE,
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationDISORDERS OF THE SMALL INTESTINE MALABSORPTION SYNDROMES I.
DISORDERS OF THE SMALL INTESTINE MALABSORPTION SYNDROMES I. Gyula Mózsik M. D., Sc. D.(med.) University of Pécs 2008 DEFINITIONS: These medical symptomes include all of the clinical pictures in patients
More informationDiagnosis of chronic Pancreatitis. Christoph Beglinger, University Hospital Basel, Switzerland
Diagnosis of chronic Pancreatitis Christoph Beglinger, University Hospital Basel, Switzerland Pancreatitis Pancreas Pancreas - an organ that makes bicarbonate to neutralize gastric acid, enzymes to digest
More informationHompes Method. Practitioner Training Level II. Lesson Eight Part 1C SIBO Protocols
Hompes Method Practitioner Training Level II Lesson Eight Part 1C SIBO Protocols Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of Health For The People
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE. Coeliac disease: recognition, assessment and management of coeliac disease
Appendix B: NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Coeliac disease: recognition, assessment and management of coeliac disease 1.1 Short title Coeliac disease 2 The remit
More informationMalabsorption is characterized by defective absorption of: Fats fat- and water-soluble vitamins Proteins Carbohydrates Electrolytes Minerals water
Malabsorption Malabsorption is characterized by defective absorption of: Fats fat- and water-soluble vitamins Proteins Carbohydrates Electrolytes Minerals water presents most commonly as chronic diarrhea
More informationFollow-up of Celiac Disease
Follow-up of Celiac Disease Benjamin Lebwohl MD, MS Director of Clinical Research Celiac Disease Center Columbia University celiacdiseasecenter.org BL114@columbia.edu @BenjaminLebwohl Disclosures None
More informationEsophageal Disorders. Gastrointestinal Diseases. Peptic Ulcer Disease. Wireless capsule endoscopy. Diseases of the Small Intestine 7/24/2010
Esophageal Disorders Gastrointestinal Diseases Fernando Vega, MD HIHIM 409 Dysphagia Difficulty Swallowing and passing food from mouth via the esophagus Diagnostic aids: Endoscopy, Barium x ray, Cineradiology,
More informationEffect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer
Turk J Gastroenterol 2016; 27: 227-32 Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer INTESTINE Sufang Liang 1, Lin Xu 1, Dongsheng Zhang 2,
More informationNutritional Management in Enterocutaneous fistula Dr Deepak Govil
Nutritional Management in Enterocutaneous fistula Dr Deepak Govil MS, PhD (GI Surgery) Senior Consultant Surgical Gastroenterology Indraprastha Apollo Hospital New Delhi What is enterocutaneous fistula
More informationFood Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence
Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence Maria Vazquez Roque, MD, MSc Assistant Professor Gastroenterology and Hepatology 2010 MFMER slide-1 Objectives Gluten-free
More informationROLE OF THE GUT BACTERIA
ROLE OF THE GUT BACTERIA Our Good Bacteria In a perfect world, we would all have a proper ratio of good bacteria And what could this proper ratio do for us? The knowledge of the connections between our
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More informationVictor Tambunan Department of Nutrition Faculty of Medicine Universitas Indonesia
Victor Tambunan Department of Nutrition Faculty of Medicine Universitas Indonesia 1 References Krause s Food & Nutrition Therapy 12th ed., 2008 ---- L.K. Mahan & S. Escott-Stump Modern Nutrition in Health
More informationClinical Trial: The Association Between Rifaximin And Partially Hydrolyzed Guar Gum Is More Effective Than Rifaximin Alone In Eradicating SIBO
Clinical Trial: The Association Between Rifaximin And Partially Hydrolyzed Guar Gum Is More Effective Than Rifaximin Alone In Eradicating SIBO Manuele Furnari, Andrea Parodi, Lorenzo Gemignani, Edoardo
More informationIBS The Physiologist s Perspective
IBS The Physiologist s Perspective Dr Anthony R. Hobson PhD Consultant Clinical Scientist, London The Functional Gut Clinic Reclaiming the F word The f-word functional has become a by-word for failure
More informationCoeliac Disease: Diagnosis and clinical features
Coeliac Disease: Diagnosis and clinical features Australasian Gastrointestinal Pathology Society AGM 28 Oct 2016 Dr. Hooi Ee Gastroenterologist, Sir Charles Gairdner Hospital Coeliac disease Greek: koiliakos
More informationBacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3.2 0.9-26.8 U/g 1.2 0.2-3.3 mg/g 2.2 1.3-8.6 micromol/g 1.1 1.3-23.7 mg/g 1.1 0.2-3.5 mg/g Rare 1.0 0.2-8.8 mg/g Rare 4.4 2.6-32.4 mg/g 64.6 >= 13.6 micromol/g Bacteriology
More informationRADIATION INDUCED SMALL BOWEL DISEASE. Dr Mnguni Supervisor: Dr Lohlun Radiation Oncology
RADIATION INDUCED SMALL BOWEL DISEASE Dr Mnguni Supervisor: Dr Lohlun Radiation Oncology INTRODUCTION Radiation therapy is not regularly indicated in the treatment of small bowel disease. Reasons are complex
More informationRefractory celiac disease (RCD) KASSEM BARADA LEBANESE SOCIETY OF GASTROENTEROLOGY NOVEMBER, 2014
Refractory celiac disease (RCD) KASSEM BARADA LEBANESE SOCIETY OF GASTROENTEROLOGY NOVEMBER, 2014 Case scenario (1) A 49 year woman presents with intermittent watery diarrhea and bloating of two years
More informationPROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT PROBIOTICS: WHAT ARE THEY, AND HOW DO THEY WORK? Karen Jensen, (Retired ND)
PROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT Karen Jensen, (Retired ND) Today many people are aware of the benefits of maintaining a healthy gut. As a result, probiotic use is becoming ever more popular.
More informationLactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth
Alimentary Pharmacology & Therapeutics Lactose intolerance in patients with chronic functional diarrhoea: the role of small intestinal bacterial overgrowth J. ZHAO*, M. FOX,à,,Y.CONG*,H.CHU*,Y.SHANG*,M.FRIED,
More informationThere is no single IBD diet
Nutrition and IBD There is no single IBD diet Nutrition plays an important role in health, during times of IBD disease activity as well as during remission. Although diet does not cause or cure IBD, the
More informationnutrition as part of the therapeutic
Science & Research Original Contribution Bacterial overgrowth: nutrition as part of the therapeutic concept Small Intestinal Bacterial Overgrowth (SIBO) Katharina Gewecke, Silya Nannen-Ottens Peer-reviewed
More informationEtiology, Assessment and Treatment
Etiology, Assessment and Treatment Andrew Tinsley MD, MS Associate Director of IBD Center Assistant Professor of Medicine Penn State College of Medicine Abbvie Janssen Nestle 1 To review the prevalence
More informationSummary for the Diagnosis of Gluten-Sensitive Entropathy Celiac Disease
Summary for the Diagnosis of Gluten-Sensitive Entropathy Celiac Disease Celiac disease is an immune medical condition that is caused by ingestion of gluten in genetically susceptible individuals. The damage
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Coeliac Disease
Southern Derbyshire Shared Care Pathology Guidelines Coeliac Disease Purpose of Guideline When and how to investigate patients for Coeliac Disease What the results mean When and how to refer patients Monitoring
More informationClinical Policy: Rifaximin (Xifaxan) Reference Number: ERX.NPA.40 Effective Date:
Clinical Policy: (Xifaxan) Reference Number: ERX.NPA.40 Effective Date: 06.01.15 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationGut Microbes: Systemic Disease. Mark Pimentel, MD. Cedars-Sinai Medical Center. Mark Pimentel, MD, FACG
Gut Microbes: Role in Health, IBS, GI and Systemic Disease Mark Pimentel, MD Director, GI Motility Program Cedars-Sinai Medical Center 1 Lacks cellulase cannot breakdown cellulose Depends completely on
More informationP A T I E N T H A N D B O O K
PATIENT HANDBOOK Heal Your Gut, Heal Your Body The gastrointestinal (GI) tract is one of the most sophisticated systems of the human body. We often think of the GI tract for its primary role in digesting
More informationDeveloped September Revised May 2018; June 2017; June 2015; October 2013; December 2011; April 2010; December 2006.
Texas Vendor Drug Program Drug Use Criteria: Rifaximin (Xifaxan ) Publication History Developed September 2006. Revised May 2018; June 2017; June 2015; October 2013; December 2011; April 2010; December
More informationNew Developments in Irritable Bowel Syndrome
New Developments in Irritable Bowel Syndrome Mark Pimentel, MD, FRCP(C) Director, GI Motility Program Cedars-Sinai Medical Center IBS Forks in the Road Not all decisions in how to handle IBS made things
More informationSequioa Education Systems, Inc. 1
Functional Diagnostic Medicine Training Program Module 2 The Functional Diagnostic Medicine Approach in the Treatment of Gastrointestinal Dysfunction and Disease Dr. Wayne L. Sodano, D.C., D.A.B.C.I. &
More informationP R E S E N T S Dr. Mufa T. Ghadiali is skilled in all aspects of General Surgery. His General Surgery Services include: General Surgery Advanced Laparoscopic Surgery Surgical Oncology Gastrointestinal
More informationA Trip Through the GI Tract: Common GI Diseases and Complaints. Jennifer Curtis, MD
A Trip Through the GI Tract: Common GI Diseases and Complaints Jennifer Curtis, MD Colon Cancer How does it develop? Most cancers arise from polyps Over time these can turn into cancer Combination of genetic
More information6.2.1 Exocrine pancreatic insufficiency
6.2.1 Exocrine pancreatic insufficiency Authors: Jean Louis Frossard, Alain Sauty 1. INTRODUCTION Exocrine pancreatic insufficiency is a biological and clinical condition that is characterized by a progressive
More informationUsing Antibiotics in IBS-D Patients
Using Antibiotics in IBS-D Patients Brennan M. R. Spiegel, MD, MSHS A 32-year-old woman with a long-standing history of intermittent abdominal pain and diarrhea was referred to a gastroenterologist due
More information